These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31325145)

  • 1. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Pentsova EI; Mellinghoff IK; Nolan C; Gavrilovic I; DeAngelis LM; Abrey LE; Holland EC; Omuro A; Lacouture ME; Ludwig E; Lassman AB
    Ann Clin Transl Neurol; 2020 Apr; 7(4):429-436. PubMed ID: 32293798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
    Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
    Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
    Matsumoto K; Shichino H; Kawamoto H; Kosaka Y; Chin M; Kato K; Mugishima H
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
    Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
    Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
    Iwamoto FM; Lamborn KR; Robins HI; Mehta MP; Chang SM; Butowski NA; Deangelis LM; Abrey LE; Zhang WT; Prados MD; Fine HA
    Neuro Oncol; 2010 Aug; 12(8):855-61. PubMed ID: 20200024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
    Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
    Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
    Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
    Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of Dovitinib in recurrent glioblastoma.
    Sharma M; Schilero C; Peereboom DM; Hobbs BP; Elson P; Stevens GHJ; McCrae K; Nixon AB; Ahluwalia MS
    J Neurooncol; 2019 Sep; 144(2):359-368. PubMed ID: 31292802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
    Silvani A; De Simone I; Fregoni V; Biagioli E; Marchioni E; Caroli M; Salmaggi A; Pace A; Torri V; Gaviani P; Quaquarini E; Simonetti G; Rulli E; D'Incalci M;
    J Neurooncol; 2019 May; 142(3):455-462. PubMed ID: 30726533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
    Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
    J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
    Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
    Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
    Ahluwalia MS; Ozair A; Drappatz J; Ye X; Peng S; Lee M; Rath S; Dhruv H; Hao Y; Berens ME; Walbert T; Holdhoff M; Lesser GJ; Cloughesy TF; Sloan AE; Takebe N; Couce M; Peereboom DM; Nabors B; Wen PY; Grossman SA; Rogers LR
    Clin Cancer Res; 2024 Aug; 30(15):3167-3178. PubMed ID: 38836759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.